Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Introduction: Hemophilic arthropathy is a common complication of hemophilia, characterized by chronic pain, functional limitation, and impaired quality of life. Cognitive-emotional factors such as catastrophizing and kinesiophobia significantly influence the pain experience, supporting the rationale for interventions grounded in the biopsychosocial model and pain neuroscience education.
Objective: To evaluate the efficacy of an educational program based on pain neurobiology, emotional regulation, and cognitive-behavioral strategies on the pain experience in adult patients with hemophilic arthropathy.
Methods: A randomized, controlled clinical trial with two parallel groups (intervention and control) and three assessment time points (pre-intervention, post-intervention, and 6-month follow-up) will be conducted. A total of 70 adult patients with hemophilia A or B and a diagnosis of hemophilic arthropathy with chronic pain will be enrolled and randomly assigned in a 1:1 ratio. The intervention group will receive a structured educational program consisting of three 60-minute sessions focused on pain neurobiology, emotional regulation, cognitive restructuring, coping strategies, and physiological downregulation techniques, including supervised physical activity as an analgesic strategy. The control group will continue with usual care without additional educational intervention. The primary outcome will be pain intensity and pain interference, assessed using the Brief Pain Inventory. Statistical analyses will be performed using repeated-measures ANOVA, with the Group Ă— Time interaction considered the primary effect of interest, under the intention-to-treat principle.
Expected Results: It is anticipated that the intervention group will demonstrate a statistically and clinically significant reduction in pain intensity and pain-related functional interference compared with the control group. A sustained clinical improvement at six months is also expected, supporting the utility of structured educational interventions as a safe and complementary strategy in the management of chronic pain in patients with hemophilic arthropathy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental group | Experimental | Patients with hemophilia allocated to the intervention group will receive a structured pain education program delivered through targeted educational sessions. |
|
| Control group | No Intervention | Participants allocated to the control group will not receive physiotherapy sessions based on pain education and will continue with their usual routine of physical activity and exercise. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Educational group | Other | Patients with hemophilia will receive a structured pain education program delivered through targeted educational sessions. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of Pain Severity and Pain-Related Interference in Daily Life | Pain severity and pain-related interference in daily life will be assessed using the Spanish version of the Brief Pain Inventory (BPI). This instrument evaluates both the intensity of pain and its impact on daily functioning, including general activity, ambulation, usual work, mood, sleep, social relationships, and enjoyment of life. It provides separate scores for pain severity and pain interference, with higher scores indicating greater pain intensity or greater perceived functional impact | Baseline, in the week following completion of the intervention, and at the 6-month follow-up period |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of Kinesiophobia | This variable will be assessed using the Spanish version of the Tampa Scale for Kinesiophobia (TSK). This scale evaluates kinesiophobia, defined as an excessive and irrational fear of movement and physical activity associated with the expectation of pain or injury. The instrument provides a total score reflecting the degree of fear-avoidance related to movement, with higher scores indicating greater levels of kinesiophobia. |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of Age | This sociodemographic variable will be used to characterize the sample and control for potential confounding factors and will be recorded as a quantitative variable (in years). | Baseline |
| Measurement of Marital Status |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rubén Cuesta-Barriuso, PhD | Contact | 0034 985103386 | cuestaruben@uniovi.es |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universidad de Oviedo | Oviedo | Principality of Asturias | 33006 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006467 | Hemophilia A |
| D059350 | Chronic Pain |
| ID | Term |
|---|---|
| D025861 | Blood Coagulation Disorders, Inherited |
| D001778 | Blood Coagulation Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline, in the week following completion of the intervention, and at the 6-month follow-up period |
| Measurement of Pain Catastrophizing | This variable will be assessed using the Spanish version of the Pain Catastrophizing Scale (PCS). This instrument measures pain catastrophizing, defined as a negative cognitive-affective response to actual or anticipated pain. The questionnaire evaluates dimensions such as rumination, magnification, and helplessness, providing a total score in which higher values reflect a greater degree of catastrophizing thinking. | Baseline, in the week following completion of the intervention, and at the 6-month follow-up period |
| Measurement of Health-Related Quality of Life | This variable will be assessed using the Spanish version of the Short Form-36 Health Survey (SF-36). This instrument evaluates health-related quality of life and consists of 36 items covering eight domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health, including one health transition item. A specific score is calculated for each domain, with higher values indicating a better perceived health status. Scores range from 0 to 100 for each dimension. | Baseline, in the week following completion of the intervention, and at the 6-month follow-up period |
| Measurement of Anxiety | This variable will be assessed using the Spanish version of the Hospital Anxiety and Depression Scale (HADS). This questionnaire evaluates anxiety symptomatology in clinical populations, providing a specific score for the anxiety subscale, with higher values indicating a greater presence of anxious symptoms. | Baseline, in the week following completion of the intervention, and at the 6-month follow-up period |
| Measurement of Illness Perception | This variable will be assessed using the Spanish version of the Brief Illness Perception Questionnaire (BIPQ). This instrument evaluates illness perception, defined as the set of cognitive and emotional beliefs and representations that a patient holds regarding their disease. The questionnaire assesses dimensions such as perceived consequences, personal control, concern, illness coherence (understanding of the disease), and emotional response, yielding scores that reflect the degree of perceived illness threat. | Baseline, in the week following completion of the intervention, and at the 6-month follow-up period |
| Measurement of Physical Activity Level | This variable will be assessed using the International Physical Activity Questionnaire (IPAQ). This instrument evaluates the level of physical activity, allowing participants to be classified according to their activity level and enabling quantification of physical activity performed across different contexts. This variable will be included to describe the study sample and to explore its potential influence on pain perception and on the outcomes of the intervention. | Baseline, in the week following completion of the intervention, and at the 6-month follow-up period |
This sociodemographic variable will be used to characterize the sample and control for potential confounding factors and will be recorded as an ordinal variable (single / married-partnered / divorced / widowed).
| Baseline |
| Measurement of Educational Level | This sociodemographic variable will be used to characterize the sample and control for potential confounding factors and will be recorded as an ordinal variable (primary education / secondary education / vocational training / university education). | Baseline |
| Measurement of Employment Status | This sociodemographic variable will be used to characterize the sample and control for potential confounding factors and will be recorded as an ordinal variable (employed - salaried / self-employed / unemployed / retired). | Baseline |
| Measurement of Type of Hemophilia | This clinical variable will be used to characterize the sample and control for potential confounding factors and will be recorded as a dichotomous variable (hemophilia A / hemophilia B). | Baseline |
| Measurement of Hemophilia Severity | This clinical variable will be used to characterize the sample and control for potential confounding factors and will be recorded as an ordinal variable (severe / moderate / mild). | Baseline |
| Measurement of Type of Medical Treatment | This clinical variable will be used to characterize the sample and control for potential confounding factors and will be recorded as a dichotomous variable (on-demand / prophylaxis). | Baseline |
| Measurement of Inhibitor Status | This clinical variable will be used to characterize the sample and control for potential confounding factors and will be recorded as a dichotomous variable (yes / no). | Baseline |
| Measurement of Regular Analgesic Medication Use | This clinical variable will be used to characterize the sample and control for potential confounding factors and will be recorded as a dichotomous variable (yes / no) | Baseline |
| D020147 | Coagulation Protein Disorders |
| D006474 | Hemorrhagic Disorders |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |